Vivaldi Biosciences


Developing More Effective Flu Vaccines

Vivaldi Biosciences Inc. is a clinical-stage biotechnology company developing live attenuated influenza vaccines (LAIVs) to address the most pressing public health issues of influenza: the need for a rapid and effective response to emerging pandemics with vaccines that are easily administered, safe and protective, and the need for vaccines that protect the most vulnerable populations – seniors and very young children – against seasonal influenza. These age groups suffer disproportionately from influenza and its serious complications, but are poorly served by available vaccines.

Vivaldi’s candidate LAIVs have completed four clinical trials, demonstrating preliminary safety and efficacy against five different influenza strains, including H5N1 (“bird flu”). Through a Cooperative Research and Development Agreement (CRADA) with the National Institute of Allergy and Infectious Diseases (NIAID), Vivaldi is developing a LAIV against H7N9, another avian-origin strain with pandemic potential. Vivaldi also is pursuing clinical development programs for LAIVs against seasonal influenza, with the goal of demonstrating safety and superior efficacy in older and elderly adults, and in young children.


Home | About | Management Team | Board of Directors | Scientific Advisors | Product Development | Publications | News and Events | Contact